Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
OBJECTIVE
To assess the efficacy and safety of switching patients from bilateral latanoprost to bimatoprost in 1 eye while maintaining latanoprost in the fellow eye.


METHODS
This prospective, open-label, multicenter, uniocular (within-eye control) study was conducted from March 2005 to February 2007; 105 patients with glaucoma or ocular hypertension were enrolled. At baseline, patients using bilateral latanoprost were switched to bimatoprost treatment in 1 eye (study eye) and continued latanoprost treatment in the fellow eye (control eye). At 12 weeks, patients were offered bilateral bimatoprost for 12 additional weeks.


RESULTS
At week 12, the mean difference in intraocular pressure (IOP) from baseline was -3.0 mm Hg in study eyes and -1.6 mm Hg in control eyes, which equates to a further -1.4 mm Hg (95% confidence limits: -1.9, -0.9) reduction in IOP in study eyes compared with control eyes (P<0.0001). Overall, 27% (28/104) more study eyes had > or = -2.5 mm Hg reduction in IOP than control eyes (P<0001). At week 24, the mean difference in IOP from baseline was -2.8 mm Hg for study eyes and for control eyes that had switched to bimatoprost. Conjunctival hyperemia occurred more frequently and was more severe in bimatoprost-treated eyes at week 12 than at baseline (P<0.001). No patients withdrew from treatment because of conjunctival hyperemia.


CONCLUSIONS
Clinically, these data suggest that switching patients from latanoprost to bimatoprost may result in further improvement in IOP control.
Casson
Robert J
RJ
South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, South Australia 5000, Australia. robert.casson@adelaide.edu.au
Liu
Lance
L
Graham
Stuart L
SL
Morgan
William H
WH
Grigg
John R
JR
Galanopoulos
Anna
A
Crawford
Andrew
A
House
Philip H
PH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003229:Conjunctival Diseases / Q000139:chemically induced; D018592:Cross-Over Studies; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D019233:Retreatment; D016896:Treatment Outcome
D000577:Amides; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost